ArticleaBIOTECH2026
Engineering high-efficiency mutants of the transposase ISDra2 TnpB via protein-generative models and energy-optimized design.
Article in aBIOTECH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transposon-associated TnpB is a compact and versatile gene editor that holds significant promise in the life sciences. However, current engineering strategies for TnpB are limited, resulting in low cleavage efficiency in mammalian cells that restricts its broader use. In this study, we developed a method termed TnpB-GMRE, which integrates a generative protein model for TnpB with a virtual screening pipeline based on the minimum recovery rate and energy minimization. From 100,000 generated sequences, we selected the top five candidates for experimental assessment. Without the use of enrichment strategies such as flow cytometry or antibiotic selection, three of the five mutants displayed higher editing activity across four target sites. Among them, the TnpB-TD mutant achieved the highest editing activity (17.7%), representing a 50% increase compared to the original ISDra2 TnpB from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.